Following promising results from this recent trail, the combination of Moderna’s new mRNA-4157 and KEYTRUDA has been granted Breakthrough Therapy Designation by the FDA in the U.S., and accepted into the Priority Medicines scheme by the European Medicines Agency, for the treatment of high-risk melanoma.
For decades researchers have been trying to develop a vaccine for the deadly respiratory disease. It looks like 2023 will be the landmark year where not only one, but possibly three different vaccines are approved.
The trial is expected to run until mid-2023. By that point it is hoped one of the three formulations will have demonstrated robust immune responses and Phase 2 trials can commence.
The clinical trials will start on August 19 and end sometime around spring 2023, according to the National Institutes of Health’s trial registry. They will involve 56 HIV-negative participants aged 18 to 56.